NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free CKPT Stock Alerts $1.90 +0.01 (+0.53%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.84▼$1.9350-Day Range$1.39▼$2.0752-Week Range$1.30▼$3.62Volume156,510 shsAverage Volume424,177 shsMarket Capitalization$67.81 millionP/E RatioN/ADividend YieldN/APrice Target$22.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Checkpoint Therapeutics alerts: Email Address Checkpoint Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,089.5% Upside$22.60 Price TargetShort InterestBearish12.68% of Float Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment0.09Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to $0.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector367th out of 928 stocksPharmaceutical Preparations Industry170th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Checkpoint Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.68% of the float of Checkpoint Therapeutics has been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Checkpoint Therapeutics has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 1.7 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Checkpoint Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CKPT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of Checkpoint Therapeutics is held by institutions.Read more about Checkpoint Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Checkpoint Therapeutics are expected to grow in the coming year, from ($1.29) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Checkpoint Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Checkpoint Therapeutics Stock (NASDAQ:CKPT)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More CKPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CKPT Stock News HeadlinesMay 31 at 9:40 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointMay 30 at 4:30 PM | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 30 at 4:30 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 29 at 3:01 PM | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPTMay 29 at 9:52 AM | msn.comCheckpoint Zoo Documentary Poster Sets Up A 2022 Ukrainian Animal Rescue StoryMay 28, 2024 | markets.businessinsider.comIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 28, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 27, 2024 | markets.businessinsider.comUPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 26, 2024 | sfgate.com2 Arrested For Driving Under The Influence, 32 Ticketed At CheckpointMay 24, 2024 | prnewswire.comFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 24, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 23, 2024 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 22, 2024 | prnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPTMay 20, 2024 | stockhouse.comUPCOMING CKPT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Checkpoint Therapeutics, Inc. Investors to Join the Class Action Lawsuit!May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Checkpoint Therapeutics Despite FDA Setback: Solid Clinical Data Fuels Optimism for 2024 Market EntryMay 16, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTMay 15, 2024 | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPTMay 15, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmMay 14, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 13, 2024 | globenewswire.comCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | finance.yahoo.comCheckpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)May 10, 2024 | prnewswire.comCKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud LawsuitMay 10, 2024 | finanznachrichten.deCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesSee More Headlines Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$22.60 High Stock Price Target$47.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,089.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,850,000.00 Net Margins-50,336.89% Pretax Margin-76,938.23% Return on EquityN/A Return on Assets-749.84% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.54 Sales & Book Value Annual Sales$100,000.00 Price / Sales678.11 Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-6.55Miscellaneous Outstanding Shares35,690,000Free Float34,937,000Market Cap$67.81 million OptionableOptionable Beta1.00 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. James F. Oliviero III (Age 48)C.F.A., President, CEO & Director Comp: $921.59kMr. William Garrett Gray (Age 37)CFO, Corporate Secretary & Treasurer Comp: $409.12kKey CompetitorsLeap TherapeuticsNASDAQ:LPTX23andMeNASDAQ:MEAdlai NortyeNASDAQ:ANLEnanta PharmaceuticalsNASDAQ:ENTAAtai Life SciencesNASDAQ:ATAIView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Sold 114,200 shares on 5/16/2024Ownership: 0.138%Vanguard Group Inc.Bought 369,586 shares on 5/10/2024Ownership: 2.572%Choreo LLCBought 38,672 shares on 5/2/2024Ownership: 0.162%Lindbrook Capital LLCBought 30,000 shares on 4/25/2024Ownership: 0.084%B. Riley Wealth Advisors Inc.Bought 114,200 shares on 3/15/2024Ownership: 0.694%View All Insider TransactionsView All Institutional Transactions CKPT Stock Analysis - Frequently Asked Questions Should I buy or sell Checkpoint Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CKPT shares. View CKPT analyst ratings or view top-rated stocks. What is Checkpoint Therapeutics' stock price target for 2024? 5 analysts have issued 1-year price objectives for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they expect the company's stock price to reach $22.60 in the next year. This suggests a possible upside of 1,089.5% from the stock's current price. View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts. How have CKPT shares performed in 2024? Checkpoint Therapeutics' stock was trading at $2.29 at the start of the year. Since then, CKPT stock has decreased by 17.0% and is now trading at $1.90. View the best growth stocks for 2024 here. Are investors shorting Checkpoint Therapeutics? Checkpoint Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,970,000 shares, an increase of 12.8% from the April 30th total of 3,520,000 shares. Based on an average trading volume of 406,900 shares, the short-interest ratio is presently 9.8 days. Approximately 12.7% of the company's shares are sold short. View Checkpoint Therapeutics' Short Interest. When is Checkpoint Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CKPT earnings forecast. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced its earnings results on Friday, March, 22nd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.36. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.09 million. When did Checkpoint Therapeutics' stock split? Checkpoint Therapeutics's stock reverse split on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL). Who are Checkpoint Therapeutics' major shareholders? Checkpoint Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.57%), Choreo LLC (0.16%), B. Riley Wealth Advisors Inc. (0.14%), Lindbrook Capital LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James F Oliviero III and William Garrett Gray. View institutional ownership trends. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CKPT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBill Clinton Backing Biden Replacement???The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.